donanemab
donanemab: 9 clinical trials tracked.
donanemab evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about donanemab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (9)
Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1
Primary endpoint: Reduction of brain tau deposition as measured by tau positron emission tomography (PET)
A Phase 4, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of Donanemab in Indian Participants With Early Symptomatic Alzheimer's Disease
Primary endpoint: Number of Participants with Any Occurrence of Amyloid-Related Imaging Abnormalities (ARIA)
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Primary endpoint: Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
Primary endpoint: Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB)
A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Primary endpoint: Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS)
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease
Primary endpoint: Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Primary endpoint: Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Primary endpoint: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Primary endpoint: Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score